PEDAL THeCAUSE™

ROI REPORT

2017 Update

7:1 ROI } **Within 5 years of investment, every $1 donated to cancer research from Pedal the Cause has on average earned an additional $7 in federal funding**

Your Pedal the Cause dollars at work:

Todd Fehniger, MD, PhD
7x Pedal the Cause Rider & Fundraiser

Todd Fehniger, MD, PhD received a $200,000 award from the Siteman Investment Program* (SIP) in 2015 for his project titled "Memory-like natural killer (NK) cells for cancer immunotherapy." For patients with AML not eligible to receive a BMT, Dr. Fehniger's team has developed a new approach (cytokine-induced memory-like, or CIML, differentiation) which involves activating immune cells (NK cells) to enhance their ability to kill leukemia cells when transferred into a patient. The goal of his SIP project was to improve the understanding of how these CIML NK cells are generated, and how they are able to better eliminate leukemia, with hopes that they could make this treatment even more effective in the future. With promising results in the laboratory, **Dr. Fehniger recently received a $2 million grant from the National Cancer Institute** to complete a first-in-human phase 1/2 clinical trial to test this novel approach for patients with AML not eligible for a BMT.

Ryan Fields, MD received a $793,000 Cancer Frontier Fund* Team Science award in 2013 for his project titled "Identifying Mechanisms of Metastasis to Improve Outcomes in Metastatic Colorectal Cancer (mCRC)." Standard treatment of mCRC is non-specific, toxic chemotherapy. Our lack of understanding of mechanisms of tumor metastasis has prevented the identification and specific targeting of pathways necessary for the cancer to spread. In this project, Dr. Fields' team performed a comprehensive analysis of 10 patients' tumors with mCRC. This unprecedented analysis utilizing cutting-edge genomic techniques yielded a "mountain" of data to analyze to find out why some tumors spread and others do not. Each of the project goals have been completed and Dr. Fields' team are in the final phase of manuscript preparation describing the clonal evolution of mCRC. These findings will challenge current paradigms of how cancers spread and evolve and may alter the staging and treatment methodologies that are current practice. To continue their research **Dr. Fields has received a subsequent $1.3 million award from the National Cancer Institute**, and team member, Christopher Maher, PhD, **received a $792,000 American Cancer Society Research Scholar Award**.

Ryan Fields, MD
3x Pedal the Cause Rider & Podium Fundraiser

Joseph Ippolito, MD, PhD
Pedal the Cause Virtual Rider & Fundraiser

Joseph Ippolito, MD, PhD received a $100,000 award from the Siteman Investment Program* (SIP) in 2016 for his project titled "Characterizing the Effects of Sexual Dimorphism on Glioma Metabolism." Glioblastoma Multiforme (GBM) is an extraordinarily aggressive cancer that comprises over half of all brain tumors. Within 1 year, Dr. Ippolito's team has successfully identified sex differences in brain tumor metabolism in both animal models and clinical samples that can be detected using multiple clinical imaging modalities (CT, MRI, PET). In response, they have developed imaging strategies in the laboratory to detect these differences at the clinical level. **In August 2017, Dr. Ippolito's findings were published in JCI: Insight and he received a National Cancer Institute award to continue his research in metabolic imaging of gliomas.**

Learn more at: pedalthecause.org/impact

***Pedal the Cause donates 100% of money raised to directly fund cancer research** through The Siteman Investment Program, The Cancer Frontier Fund and The Children's Discovery Institute. The Siteman Investment Program and The Cancer Frontier Fund are designed to award pilot funding to faculty investigators to support pioneering cancer research and produce data to leverage further external peer reviewed funding. The Children's Discovery Institute is the result of a shared vision to change the way pediatric research is conducted with an intense commitment to bring about dramatic results in pediatric care.